Comparison of Uroplakin Expression During Urothelial Carcinogenesis Induced by N-Butyl-N-(4-Hydroxybutyl)Nitrosamine in Rats and Mice
Kumiko Ogawa, Margaret St. John, Maria Luiza De Oliveira, Lora Arnold, Tomoyuki Shirai, Tung-Tien Sun and Samuel M. Cohen

Toxicol Pathol 1999 27: 645
DOI: 10.1177/019262339902700606

The online version of this article can be found at:
http://tpx.sagepub.com/content/27/6/645
Comparison of Uroplakin Expression During Urothelial Carcinogenesis Induced by N-Butyl-N-(4-Hydroxybutyl)Nitrosamine in Rats and Mice*

KUMIKO OGAWA,1,2 MARGARET ST. JOHN,1 MARIA LUIZA DE OLIVEIRA,1,4 LORA ARNOLD,1 TOMOYUKI SHIRAI,2 TUNG-TIEN SUN,3 AND SAMUEL M. COHEN1

1Department of Pathology and Microbiology and the Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198-3135, USA,
2First Department of Pathology, Nagoya City University Medical School, Nagoya 454, Japan, and
3Epithelial Biology Unit, The Ronald O. Perelman Department of Dermatology, Department of Pharmacology and Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, USA

ABSTRACT

The expression of uroplakins, the tissue-specific and differentiation-dependent membrane proteins of the urothelium, was analyzed immunohistochemically in N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)–treated rats and mice during bladder carcinogenesis. Male Fischer 344 rats were treated with 0.05% BBN in the drinking water for 10 wk and were euthanatized at week 20 of the experiment. BBN was administered to male B6D2F1 mice; it was either provided at a rate of 0.05% in the drinking water (for 26 wk) or 5 mg BBN was administered by intragastric gavage twice weekly for 10 wk, followed by 20 wk without treatment. In rats, BBN-induced, noninvasive, low-grade, papillary, transitional cell carcinoma (TCC) showed decreased uroplakin-staining of cells lining the lumen but showed increased expression in some nonluminal cells. In mice, nonpapillary, high-grade dysplasia, carcinoma in situ, and invasive carcinoma were induced. There was a marked decrease in the number of uroplakin-positive cells lining the lumen and in nonluminal cells. This occurred in normal-appearing urothelium in BBN-treated mice and in dysplastic urothelium, in carcinoma in situ, and in invasive TCC. The percentage of uroplakin-positive nonluminal cells was higher in control mice than in rats, but it was lower in the mouse than in the rat after BBN treatment. Uroplakin expression was disorderly and focal in BBN-treated urothelium in both species. These results indicate that BBN treatment changed the expression of uroplakins during bladder carcinogenesis, with differences in rats and mice being related to degree of tumor differentiation.

Keywords: Uroplakins; differentiation; bladder cancer; cell membranes

INTRODUCTION

Uroplakins are the major protein components of the asymmetric unit membrane (AUM). The AUM is a specialized plasma membrane representing urothelial terminal differentiation, which is unique to the luminal surface of superficial cells and of the intracytoplasmic vesicles (17, 20). Possible functions of the AUM include the following: it may act as a permeability barrier; it may act as a means of stabilizing the apical bladder surface; and it may act as a supramolecular device to change the surface area of the plasma membrane during expansion or contraction of the bladder. Uroplakins are synthesized in the endoplasmic reticulum, concentrated and modified in the Golgi complex, and then incorporated into the membrane of intracytoplasmic fusiform vesicles and into the plasmalemma. Uroplakins are mainly produced in cells of the superficial layer of the urothelium. Uroplakins consist of 4 components: the 27-kDa uroplakin Ia; the 28-kDa uroplakin Ib; the 15-kDa uroplakin II; and the 47-kDa uroplakin III (10, 17–20). Together they form 16-nm twisted ribbon–shaped particles that are arranged in a well-ordered, hexagonal lattice with p6 symmetry (15). These 4 uroplakins are conserved through a broad range of mammalian species, including human, monkey, cattle, sheep, pig, dog, rabbit, rat, and mouse (16).

Previous experiments investigating uroplakins in various carcinogen-treated rat bladders showed that the patterns of expression of these proteins were modified during carcinogenesis (13). In the control bladder, the luminal surface membrane of the superficial cells stains strongly positive for uroplakins, but there is no cytoplasmic staining and no staining of basal intermediate cells. The genotoxic carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) induces simple hyperplasia, in which uroplakin expression is discontinuous and disorderly, not only in the superficial cells but also in the intermediate cells. The nongenotoxic carcinogens uracil, sodium saccharin, and sodium ascorbate also induce simple hyperplasia, but the staining of the superficial cells remains continuous and orderly. Occasional intermediate cells of the bladder also stained positive for uroplakins in uracil-fed rats (13). In carcinoma induced by FANFT in rats, uroplakin expression is scarce, disorderly, and focal and is usually not present in the cells lining the bladder lumen (13).

N-Butyl-N-(4-hydroxybutyl)nitrosamine (BBN), like

* Address correspondence to: Dr. Samuel M. Cohen, Department of Pathology and Microbiology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, Nebraska 68198-3135; e-mail: scohen@unmc.edu.

4 Present address: Departamento de Patologia, Faculdade de Medicina, Unesp, Botucatu-SP, Brazil, CEP, 18618-000.
FANFT (4–6), is a genotoxic carcinogen that is widely used in animal bladder–carcinogenesis studies (2, 8). Several investigators have demonstrated that bladder carcinomas in rats are generally multiple, papillary, and noninvasive until late in the rat’s life (greater than 1 yr of age) (4, 6, 8). In contrast, bladder carcinomas in mice tend to be nonpapillary, invasive, and high grade (2). Dysplasia and carcinoma in situ occur early in the treatment (by 12 wk) (2).

In the present study, the expression patterns of uroplakins were immunohistochemically compared in rats and mice during bladder carcinogenesis induced by BBN.

**MATERIALS AND METHODS**

The use of animals in these studies followed the guidelines provided in the National Research Council’s (1996) *The Guide for Care and Use of Laboratory Animals* and was approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee.

**Rat Study.** Ten male Fischer 344 (F344) rats (Charles River Japan, Inc., Atsugi, Japan) (4 wk of age) were housed 5 to a plastic cage with hard-wood chip bedding under environmental conditions maintained at 21°C and 55% humidity. Basal diet (pelleted Oriental MF, Oriental Yeast Co., Ltd., Tokyo, Japan) was provided *ad libitum*. The BBN was obtained from Izumi Chemical Research Laboratory (Yokohama, Japan), diluted to 0.05% with tap water, and this mixture was then provided as drinking water (*ad libitum*) for 10 wk. After withdrawal of BBN administration, tap water without added chemicals was available *ad libitum*. At 20 wk, the rats were euthanatized, and urinary bladders were inflated in situ with 10% phosphate-buffered formalin, divided into longitudinal strips, and processed for routine paraffin embedding; 4–6-μm sections were stained either with hematoxylin and eosin or using immunohistochemical methods.

**Mouse Study.** Male 4-wk-old B6D2F, mice (Charles River Breeding Laboratories, Inc., Kingston, NY) were housed in plastic cages (4–6/cage) with dry corn-cob bedding. At 5 wk of age, using a weight-stratification method (12), they were randomly divided into 3 groups of 45 each. The animal room was maintained at a temperature of 22°C and a relative humidity of 50%. The BBN was purchased from the same company as was used for the rat study. BBN was administered to 2 different groups by different routes. In group 1, BBN was diluted with tap water to a concentration of 0.05%, and this mixture was given (*ad libitum*) in the drinking water during the entire 26 wk during which this group was maintained in the study. In group 2, 5 mg of BBN was administered by gastric gavage (in 0.1 ml of 20% ethanol) to each mouse twice per week for 10 wk. These mice were then maintained without treatment for an additional 20 wk (total of 30 wk for this group). As a control, the same amount of 20% ethanol was administered to mice in group 3 (twice weekly for 10 wk), and the mice were then maintained for an additional 20 wk without gavage (total of 30 wk, as in group 2). Basal diet (Prolab 3200, Agway, St. Mary’s, OH) was provided *ad libitum*. Ten mice from each group were euthanatized at week 12 of the experiment. Since few mice in group 1 remained alive and because they were all showing evidence of bladder tumors (hematuria) and/or weight loss, all surviving mice from the BBN–drinking water group were sacrificed at week 26 of the experiment. The remaining mice in groups 2 and 3 were sacrificed at week 30. The bladders were inflated in situ using Bouin’s fixative, removed, and placed in Bouin’s fixative. After fixation, the bladders were rinsed with 70% ethanol, cut longitudinally into strips, processed for routine embedding in paraffin, and stained with hematoxylin and eosin or immunohistochemical procedures.

**Immunohistochemical Analysis.** The avidin–biotin–peroxidase complex method (7) using the ABC kit (Vector Laboratories, Inc., Burlingame, CA) was performed to detect uroplakin expression. After deparaffinization, formalin-fixed rat bladder sections were heated by microwave with antigen-retrieval solution (BioGenex Laboratories, San Ramon, CA). Bouin’s-fixed mouse sections were incubated with 1% nonfat skim-milk solution. Anti-AUM antibody consisted of rabbit antiserum made against highly purified bovine AUM (17), which reacts with all 4 uroplakins and cross-reacts with the uroplakins in all other species evaluated, including rats and mice. It was applied to tissue sections at a 1:104 dilution for 2 hr. Diaminobenzidine was used as a substrate, and hematoxylin was used as a nuclear counterstain.

Typical lesions were diagnosed as simple hyperplasia, papillary and nodular (PN) hyperplasia, dysplasia, papilloma, carcinoma *in situ*, papillary carcinoma, and invasive carcinoma (2, 3). The percentage of uroplakin-positive cells was determined by evaluating approximately 300 superficial and 1,200 intermediate bladder urothelial cells in rats and approximately 100 superficial and 400 intermediate cells in mice. Statistical analyses were performed with a generalized linear model procedure (SAS Institute, Inc., Cary, NC). Multivariate analysis of variance (14) was used for multiple comparison of means for percentage data.

**RESULTS**

**Rat Study**

The typical pattern for uroplakins in control rat bladders was limited to staining of the luminal membrane of the superficial cells (Fig. 1a). The normal-appearing rat urothelium of the BBN-treated group showed the same staining pattern as was seen in control rats. In the simple hyperplasia and PN hyperplasia (Fig. 1b) that were induced in the BBN–drinking water group of rats, almost all superficial cells showed uroplakin expression. Occasional expression was also observed in intermediate cells, even when these cells were not directly adjacent to superficial cells. In rat papillary transitional cell carcinoma (Fig. 1c), which is low grade and noninvasive, some cells lining the lumen did not express uroplakins, whereas several nonluminal cells did express uroplakins. As has been shown by scanning electron microscopy (1, 9), the cells at the luminal surface of these bladder tumors are not terminally differentiated superficial cells but, rather, have microvilli on their surfaces instead. The rate of positive-staining nonluminal cells varied depending on histology.
Essentially, the more differentiated (lower grade) the tumor, the greater the expression of uroplakins that was observed in luminal cells.

**Mouse Study**

In control mice, there was staining of superficial cells similar to that seen in the rat, but there was also staining of some intermediate cells (Fig. 2a). These positive-staining intermediate cells have been reported by Lin et al (11) and were directly adjacent to positive-staining superficial cells. In contrast to the rat, there was a lack of uroplakin expression in intermediate cells and also in some superficial cells in the bladders of both groups of BBN-treated mice at week 12, even when the histology was normal by light microscopy. Further decreases in the proportion of uroplakin-positive superficial cells were seen in the simple hyperplasia in the BBN-treated groups (Fig. 2b). In the rat, the sequence of bladder carcinogenesis progresses through PN hyperplasia, papillomas, and finally, through low-grade, papillary carcinomas. In contrast, bladder carcinogenesis in mice administered BBN in the drinking water or by gavage progresses through a sequence characterized by mild simple hyperplasia, dysplasia, flat carcinoma in situ, and then invasive, nonpapillary, high-grade carcinoma. Three carcinomas in situ were found in the BBN–drinking water group at week 12, and invasive carcinoma was observed in 1 BBN-gavage–treated mouse at week 12 and in most mice of both BBN-treated groups at the end of the experiment. Only a few uroplakin-positive cells were observed in any of these in situ or invasive carcinomas (Fig. 2c).

Severe hydronephrosis was often found in mice that had been treated with BBN and that died during the course of the experiment, and by the end of the experiment, renal pelvic carcinomas also developed in response to both routes of BBN treatment. The uroplakin-expression pattern in the renal pelvis lesions was similar to that seen in the bladder—characterized by occasional luminal-lining cells that did not stain for uroplakins and few positive-staining intermediate cells in the early hyperplastic lesions (Fig. 2d). Cells in the pelvic carcinomas rarely stained for uroplakins. A similar pattern of staining was seen in the ureter. Occasional uroplakin expression was also observed in the cells lining the renal papilla.

The percentages of uroplakin-positive cells in the various bladder lesions are summarized in Table I. At the luminal surface, 100% of the superficial cells of control animals were uroplakin positive in the rat and mouse. BBN treatment caused a significant decrease in uroplakin expression in mouse urothelium in all lesions through carcinoma. Normal-appearing epithelium in these mice also showed significantly decreased uroplakin expression. The decreased expression was greater in the mouse than in the rat.

In nonluminal urothelial cells, the percentages of uroplakin-positive cells in control mice were higher than those in rats. Following BBN treatment, the number of uroplakin-positive cells significantly increased in the rat, but this number decreased in the mouse.

In the rat, several luminal-lining cells of papillary carcinomas showed uroplakin expression. Dysplasia and carcinoma in situ in the mouse showed some uroplakin expression at the luminal surface, but invasive carcinomas showed few cells that were expressing uroplakin.

**DISCUSSION**

In the present experiment, we demonstrated alterations in uroplakin expression following BBN administration in both rat and mouse bladder urothelium. Although changes in expression differed in rats and mice, they appeared early during BBN-induced urothelial carcinogenesis in both species. Two types of changes were recognized in both species: 1) the disappearance of uroplakin expression in the cells lining the lumen; and 2) the appearance of occasional intermediate cells that expressed uroplakins in a disorderly and discontinuous pattern. With the development of carcinomas, uroplakin expression gradually disappeared, except for rare positively stained cells. These phenomena were also observed in our previous study in rats that were administered FANFT, uracil, sodium saccharin, or sodium ascorbate (13). The uroplakin-expression pattern in BBN-treated rat bladder during the morphologic evolution of carcinogenesis was similar to that observed with FANFT, another genotoxic carcinogen. Similar expression was observed, despite formalin fixation, in the BBN rat experiment, in contrast to that observed with Bouin’s fixation in the FANFT rat experiment. The changes appeared more gradually and were less severe in rats that were administered nongenotoxic chemicals, such as uracil, sodium saccharin, or sodium ascorbate.

The change in expression of uroplakins in the urothelium during bladder carcinogenesis represents alterations in differentiation that occur during the process. Uroplakins are the major proteins making up the asymmetric unit membrane that is characteristic of terminal differentiation of the urothelium (17). During carcinogenesis, the ability of the urothelium to terminally differentiate is gradually lost. This has been demonstrated by the loss of the microridge pattern on the urothelial luminal surface, as observed with scanning electron microscopy (1, 9), by the loss of fusiform vesicles with asymmetric unit membrane (1), and in the present study, by the loss of uroplakin expression. With genotoxic carcinogens such as BBN or FANFT, the expression of uroplakins decreases very early in the process, even when there is only slight simple hyperplasia. With progression of the lesions to carcinoma, uroplakin expression decreases markedly, and occasionally, it completely disappears in invasive carcinomas. Although staining for uroplakins is discontinuous in cells lining the lumen of the bladder in hyperplasia, these cells generally are not the usual fully differentiated “umbrella” superficial cells of the urothelium, but rather, they more closely resemble the smaller intermediate cells of the urothelium. Expression of uroplakins in these cells or in intermediate cells away from the lumen may represent aborted attempts at differentiation. The lack of AUM indicates that terminal differentiation has not occurred.

Bladder carcinogenesis in the rat, when induced by BBN or FANFT, usually produces low-grade papillary carcinomas. These only infrequently become invasive or high-grade in nature, and they do so at much later times...
than the length of time of the present experiment allowed (3, 8). These tumors most closely resemble low-grade papillary bladder carcinomas in humans. The presence of some uroplakin expression in these tumors is indicative of the well-differentiated nature of the lesions. In contrast, bladder carcinogenesis in BBN-treated mice, whether the BBN is administered in the drinking water or by gavage, produces hyperplasia, with the rapid appearance of dysplasia and carcinoma in situ. The bladder tumors that result are high-grade, nonpapillary, invasive carcinomas (2) that are similar to the nonpapillary bladder tumors of humans. Given the poorly differentiated nature of these lesions, even early on during carcinogenesis, it is not surprising that uroplakin expression is more severely and more rapidly lost than in the rat model.

In the present study, the loss of uroplakin expression appeared to be more severe in the mice given BBN by drinking water than in those given BBN by gavage. BBN administration via drinking water also caused a higher incidence of invasive bladder carcinoma, compared with BBN administered by gavage. This might be related to the total doses of BBN that were provided by administration of BBN in the drinking water compared with the doses provided by gavage administration. Also, BBN was continuously administered for the entire experiment in the drinking water group, whereas the gavage treatment...
only lasted for 10 wk, followed by 20 wk with no treatment. Since the rate of uroplakin-positive cells in the gastric group tended to recover by week 30 in the nontumor epithelium, compared with what was observed at week 12, the alteration of uroplakin expression in simple hyperplasia appears to be partially reversible, which corresponds to the reversibility of the early histopathologic alterations.

Interestingly, uroplakin expression was also altered in BBN-treated mouse kidney pelvis, which reflects the dysplastic and carcinomatous changes produced by BBN. In contrast, FANFT- or BBN-treated F344 rat renal pelvis develops mild simple hyperplasia but not carcinomas (4), and the pelvic urothelium shows little change in uroplakin expression.

In summary, uroplakin expression is altered in urothelial cells during carcinogenesis in rats and mice and is an early event in the process, and differences between rats and mice correlate with the striking differences in the grade (differentiation) of the malignancies that develop.

ACKNOWLEDGMENTS

This work was supported by U.S. Public Health Service grants CA32513 and CA36727 from the National Cancer Institute as well as grants DK39753 and DK47529 from the National Institute of Diabetes and Digestive and Kidney Diseases. We gratefully acknowledge the advice and constructive comments of Drs. Angela Mann and Eva Uzvolgyi, the technical support of Mr. Mohamad Khachab and Ms. Traci Anderson, and the assistance of Ms. Carolyn Clark, Michelle Moore, and Denise Miller, who assisted with the preparation of this manuscript.

REFERENCES


STP HOME PAGE
Visit the World Wide Web Home Page for the Society of Toxicologic Pathologists:

http://www.toxpath.org

Contents include: headline news; information about membership; a listing of upcoming meetings; and information about Toxicologic Pathology, the official publication of the Society; as well as other STP publications.